Insmed, Inc. $INSM Shares Acquired by iA Global Asset Management Inc.

iA Global Asset Management Inc. increased its position in Insmed, Inc. (NASDAQ:INSM) by 15,973.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,682 shares of the biopharmaceutical company’s stock after acquiring an additional 26,516 shares during the period. iA Global Asset Management Inc.’s holdings in Insmed were worth $4,644,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. DNB Asset Management AS increased its holdings in shares of Insmed by 1,104.9% in the 4th quarter. DNB Asset Management AS now owns 40,918 shares of the biopharmaceutical company’s stock worth $7,121,000 after acquiring an additional 37,522 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in Insmed by 8,017.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 9,254 shares of the biopharmaceutical company’s stock valued at $1,611,000 after buying an additional 9,140 shares in the last quarter. AustralianSuper Pty Ltd bought a new position in Insmed in the 4th quarter valued at about $1,741,000. E Fund Management Hong Kong Co. Ltd. bought a new position in Insmed in the 4th quarter valued at about $124,000. Finally, Allworth Financial LP grew its position in Insmed by 20.5% in the 4th quarter. Allworth Financial LP now owns 635 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 108 shares in the last quarter.

Insmed Stock Performance

NASDAQ:INSM opened at $109.14 on Monday. Insmed, Inc. has a twelve month low of $64.85 and a twelve month high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The company has a 50-day moving average of $141.33 and a 200-day moving average of $163.25. The firm has a market cap of $23.66 billion, a price-to-earnings ratio of -18.98 and a beta of 0.89.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company had revenue of $305.96 million during the quarter, compared to analyst estimates of $300.81 million. During the same quarter last year, the firm posted ($1.42) EPS. The business’s revenue for the quarter was up 229.7% on a year-over-year basis. Analysts forecast that Insmed, Inc. will post -2.52 earnings per share for the current fiscal year.

Insider Activity

In other Insmed news, insider Michael Alexander Smith sold 19,638 shares of the company’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the sale, the insider directly owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. This represents a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Roger Adsett sold 88,060 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the sale, the chief operating officer directly owned 106,810 shares of the company’s stock, valued at $17,584,130.30. This represents a 45.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 161,193 shares of company stock worth $25,462,012. Corporate insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on INSM shares. Guggenheim decreased their target price on shares of Insmed from $230.00 to $226.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $166.00 to $212.00 in a research report on Monday, March 30th. Raymond James Financial started coverage on shares of Insmed in a research report on Friday, April 10th. They issued an “outperform” rating and a $200.00 target price for the company. Stifel Nicolaus increased their target price on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Finally, Jefferies Financial Group started coverage on shares of Insmed in a research report on Monday, March 16th. They issued a “buy” rating and a $228.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $210.95.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.